167. マルファン症候群／ロイス・ディーツ症候群 Disease details / Clinical trials / Drug dev / DR info

Aliskiren
   Samsung Medical Center
      2010   Phase 3   NCT01715207   Korea, Republic of
Aprovel
   Clinical Trials and Research Governance
      2013   Phase 2   EUCTR2010-023612-14-GB   United Kingdom
   Royal Brompton and Harefield NHS Foundation Trust
      2010   Phase 3   EUCTR2010-019302-16-GB   United Kingdom
Atenolol
   Brigham and Women's Hospital
      2007   Phase 3   NCT00723801   United States
   Cardiff University
      2006   Phase 4   NCT01295047   United Kingdom
      2005   Phase 4   EUCTR2005-000749-13-GB   United Kingdom
   Forteza, Albert, M.D.
      2008   Phase 3   NCT01145612   Spain
   New England Research Institutes
      2007   Phase 3   NCT00429364   Belgium;Canada;United States
   Samsung Medical Center
      2010   Phase 3   NCT01715207   Korea, Republic of
   University Hospital Gent
      2006   -   EUCTR2006-003991-37-BE   Belgium
   University of British Columbia
      2008   Phase 2   NCT00593710   Canada
   alberto forteza
      2008   -   EUCTR2007-001125-97-ES   Spain
Atenolol or propranolol
   National Taiwan University Hospital
      2007   Phase 2   NCT00651235   Taiwan
Blokium 50 MG comprimidos
   alberto forteza
      2008   -   EUCTR2007-001125-97-ES   Spain
Blood samples
   Hospices Civils de Lyon
      2022   -   NCT05472519   France
Bloodsampling
   University Hospital, Antwerp
      2020   -   NCT06257004   Belgium
Collection OF samples OF blood and urine
   University Hospital, Toulouse
      2022   -   NCT04970459   France
Coozar
   University Hospital Ghent
      2009   -   EUCTR2007-005862-10-BE   Belgium
Coversyl
   Bayside Health
      2004   Phase 3   NCT00485368   -
   Cardiff University
      2005   Phase 4   EUCTR2005-000749-13-GB   United Kingdom
Cozaar
   University Hospital Ghent
      2009   -   EUCTR2007-005862-10-BE   Belgium
Cozaar 50
   alberto forteza
      2008   -   EUCTR2007-001125-97-ES   Spain
Cozaar inicio 12,5 MG comprimidos recubiertos CON pelicula
   alberto forteza
      2008   -   EUCTR2007-001125-97-ES   Spain
Doxycycline 100-200MG capsules daily FOR 6 months
   University of Oxford
      2013   Phase 2   NCT01949233   United Kingdom
Doxycycline hyclate PH.EUR
   Clinical Trials and Research Governance
      2013   Phase 2   EUCTR2010-023612-14-GB   United Kingdom
Irbesartan
   Clinical Trials and Research Governance
      2013   Phase 2   EUCTR2010-023612-14-GB   United Kingdom
   Royal Brompton and Harefield NHS Foundation Trust
      2010   Phase 3   EUCTR2010-019302-16-GB   United Kingdom
Irbesartan 150-300MG capsules daily FOR 6 months
   University of Oxford
      2013   Phase 2   NCT01949233   United Kingdom
Lobivon*28CPR 5MG
   OSPEDALE POLICLINICO S. MATTEO
      2008   Phase 3   EUCTR2008-001462-81-IT   Italy
Lortaan*28CPR RIV DIV 50MG
   OSPEDALE POLICLINICO S. MATTEO
      2008   Phase 3   EUCTR2008-001462-81-IT   Italy
Losartan
   Assistance Publique - Hôpitaux de Paris
      2008   Phase 3   NCT00763893   France
   Brigham and Women's Hospital
      2007   Phase 3   NCT00723801   United States
   Forteza, Albert, M.D.
      2008   Phase 3   NCT01145612   Spain
   National Taiwan University Hospital
      2007   Phase 2   NCT00651235   Taiwan
   OSPEDALE POLICLINICO S. MATTEO
      2008   Phase 3   EUCTR2008-001462-81-IT   Italy
   University Hospital, Ghent
      2009   Phase 3   NCT00782327   Belgium
   University of British Columbia
      2008   Phase 2   NCT00593710   Canada
Losartan and nebivolol
   IRCCS Policlinico S. Matteo
      2008   Phase 3   NCT00683124   Italy
Losartan potassium
   New England Research Institutes
      2007   Phase 3   NCT00429364   Belgium;Canada;United States
   University Hospital Gent
      2006   -   EUCTR2006-003991-37-BE   Belgium
   University Hospital Ghent
      2009   -   EUCTR2007-005862-10-BE   Belgium
   alberto forteza
      2008   -   EUCTR2007-001125-97-ES   Spain
Nebivolol
   OSPEDALE POLICLINICO S. MATTEO
      2008   Phase 3   EUCTR2008-001462-81-IT   Italy
Perindopril
   Bayside Health
      2004   Phase 3   NCT00485368   -
   Cardiff University
      2006   Phase 4   NCT01295047   United Kingdom
      2005   Phase 4   EUCTR2005-000749-13-GB   United Kingdom
Valsacor
   Medical University of Gdansk
      2023   Phase 3   EUCTR2022-000513-14-PL   Poland
Valsartanum 40 MG / placebo 1
   Medical University of Gdansk
      2023   Phase 3   EUCTR2022-000513-14-PL   Poland
Valsartanum 80 MG / placebo 2
   Medical University of Gdansk
      2023   Phase 3   EUCTR2022-000513-14-PL   Poland
Valzek
   Medical University of Gdansk
      2023   Phase 3   EUCTR2022-000513-14-PL   Poland
Verapamil
   Cardiff University
      2006   Phase 4   NCT01295047   United Kingdom
Verapamil SR
   Cardiff University
      2005   Phase 4   EUCTR2005-000749-13-GB   United Kingdom
Vibrox 100MG capsules
   Clinical Trials and Research Governance
      2013   Phase 2   EUCTR2010-023612-14-GB   United Kingdom